The cell and gene therapy startups area is experiencing unprecedented growth from advancements in biotechnology, capital investment flows, and the rising demand for personalized medicine. These startups are taking the lead in delivering potential life-changing treatments for diseases that people thought were once untreatable (some cancers, genetic diseases and the long list of degenerative diseases). There is substantial global momentum in this market, and emerging economies - including India - are demonstrating an increasing capacity to contribute to the innovation pipeline and manufacturing capabilities.
Driving business growth in this area are developments in CRISPR, CAR-T therapies, stem cells studies, modified regulatory pathways that permit accelerated processes, among other fulcrums. Venture capital remains strong and forms of strategic partnerships are being brokered between startups, research institutes, and larger pharmaceutical companies to expedite startups delivery for product development. Startups are also seeking to establish scalable manufacturing and economical delivery systems to improve access to therapies, mostly in low and middleincome markets.
Startups face some substantial challenges, such as high research and development (R&D) investments, infrastructure limitations, regulatory uncertainties, and lengthy approval timeframes. Also, the need for specialized talent, supply chain reliability for...
Our subscribers play a decisive role in finalization of our annual list of Top 10 Startups in Cell and Gene Therapy - 2025 by nominating those which have served them with excellence and are praiseworthy. If you feel there is a company that deserves to be on our annual list, do write to us about them mentioning their value proposition.
 | Acadicell | With a unique approach to training, research, and product development, this cell and gene therapy firm is bridging the gap between academia and industry, while addressing the challenges in the cell and gene therapy landscape |
 | East Ocyon Bio | Focused on advanced therapies, including cell and gene therapy innovations with a mission to develop accessible, next-generation treatments and emphasizes scalable solutions in regenerative medicine and personalized immunotherapy |
 | Exrna Therapeutics | A biotech firm specializing in antisense oligonucleotide therapies and RNA interference solutions, the company strategically narrowed its focus to RNA-based therapeutics in response to the evolving needs of the biotech sector |
 | Exsegen Genomics | Offers a wide range of possibilities for cancer diagnosis and treatment, including tumor identification, tracking drug resistance and identifying new treatment targets and supports remote diagnosis through cloud-based, AIdriven algorithms that analyze unique gene patterns |
 | Immuneel | A cell and gene therapy company which has developed Qartemi (varnimcabtagene autoleucel), a CAR T-cell therapy targeting adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL) |
 | ImmunoACT | The company focus on developing cutting-edge gene and cell therapies, particularly CAR-T cell therapies for cancer with an integrated approach covering research, manufacturing, and clinical development |
 | Mediomix | The firm provides a wide range of genomics solutions in four major areas, namely academic research, clinical diagnostics, direct-to-consumer wellness, and predictive genomics |
 | NKure Therapeutics | Specializes in the research and development of Natural Killer (NK) cell-based therapies, the company focuses on oncology and infectious disease applications and aims to create off-the-shelf and allogeneic immunotherapies |
 | Transcell Biosciences | Through its research, technology, and patient care connection platform, the company has established a pathway that brings scientific breakthroughs into practical healthcare applications |
 | Vyome Therapeutics | The company has integrated scientific rigor, strategic business insight, and global execution capabilities to address unmet medical needs, with a focus on immunoinflammatory and rare disease indications |
